Overview
Doximity fiscal Q2 revenue grows 23% yr/yr, beating analysts' expectations
Adjusted EBITDA for fiscal Q2 beats consensus, rising 32% yr/yr
Company highlights growth in AI tools and user engagement
Outlook
Doximity sees Q3 revenue between $180 mln and $181 mln
Company expects Q3 adjusted EBITDA between $103 mln and $104 mln
Doximity projects FY2026 revenue between $640 mln and $646 mln
Company anticipates FY2026 adjusted EBITDA between $351 mln and $357 mln
Result Drivers
AI TOOL ADOPTION - Co attributes revenue growth to increased use of AI tools, with AI Scribe and DoxGPT users growing over 50% from prior qtr
USER ENGAGEMENT - Record 650,000 prescribers used workflow tools, contributing to revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $168.53 mln | $157.61 mln (18 Analysts) |
Q2 Net Income | $62.06 mln | ||
Q2 Adjusted EBITDA | Beat | $100.83 mln | $87.54 mln (18 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Doximity Inc is $72.50, about 11.7% above its November 5 closing price of $63.99
The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 39 three months ago
Press Release: ID:nBw2HT3Dqa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)